Basic Information
| LncRNA/CircRNA Name | TUG1 |
| Synonyms | TUG1, LINC00080, NCRNA00080, TI-227H |
| Region | GRCh38_22:30969245-30979395 |
| Ensemble | ENSG00000253352 |
| Refseq | NR_002323 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | pancreatic ductal adenocarcinoma |
| ICD-0-3 | C25.3 |
| Methods | qPCR, Western blot, Flow cytometry assay, etc. |
| Sample | The PDAC cell lines (PANC-1, PANC-28, BXPC3, SW1990). |
| Expression Pattern | up-regulated |
| Function Description | In summary, the present study revealed that TUG1 promoted the viability of PDAC cells and enhanced its resistance of gemcitabine, which might provide a theoretical basis for the development of new PDAC treatment. Surprisingly, gemcitabine combined with SCH772984 (a suppressor of ERK pathway) could reverse the drug resistance resulted from overexpression of TUG1. |
| Pubmed ID | 29960845 |
| Year | 2018 |
| Title | LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma. |
External Links
| Links for TUG1 | GenBank HGNC NONCODE |
| Links for pancreatic ductal adenocarcinoma | OMIM COSMIC |